CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.
CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.
复制标题
DOI：
10.1086/518135
复制
发表时间：
2007-07
期刊：
影响因子：
--
通讯作者：
C. Tacket;M. Levine
中科院分区：
文献类型：
--
作者：
C. Tacket;M. Levine
伤寒在世界许多地区仍然是一个重要的公共卫生问题。尽管口服Ty21a(Vivotif；Berna Biotech)和非肠道Vi多糖疫苗(Typhim Vi；Avens Pasteur)已经上市，但人们一直在寻求改进的伤寒疫苗。其中包括马里兰大学疫苗开发中心基于aroc、arrod和htrA基因缺失对伤寒沙门氏菌血清型的衰减而开发的一系列候选疫苗。这些被命名为“CVD908”、“CVD908-htrA”和“CVD909”的候选疫苗已经被开发出来，并在志愿者身上进行了测试，取得了不同的成功。这篇综述总结了指导这一疫苗开发战略合理进展的临床数据。
Typhoid fever remains an important public health problem in many parts of the world. Despite the availability of oral Ty21a (Vivotif; Berna Biotech) and parenteral Vi polysaccharide vaccine (Typhim Vi; Aventis Pasteur), improved typhoid fever vaccines have been sought. These include a series of vaccine candidates developed at the Center for Vaccine Development, University of Maryland, based on attenuation of Salmonella enterica serovar Typhi by deletions in the aroC, aroD, and htrA genes. These vaccine candidates, designated "CVD 908," "CVD 908-htrA," and "CVD 909," have been developed and tested in volunteers with variable success. This review summarizes the clinical data that directed the logical progression of this vaccine development strategy.